Journal
ONKOLOGIE
Volume 33, Issue 10, Pages 537-539Publisher
KARGER
DOI: 10.1159/000319696
Keywords
Hepatitis B Virus; Reactivation; Rituximab; Chemotherapy; Lymphoma
Categories
Ask authors/readers for more resources
The anti-CD20 monoclonal antibody rituximab has been used extensively in the treatment of B-cell lymphoma. However, several studies reported hepatitis B virus (HBV) reactivation after rituximab administration. The majority of these cases have been described in chronic carriers of HBV, whereas reactivation in occult hepatitis B carriers is relatively rare. We report a fatal case of fulminant hepatitis B that occurred in a B-cell lymphoma patient with occult hepatitis B after rituximab-containing chemotherapy, which raised the necessity of antiviral prophylaxis in this setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available